WO2002082091A3 - Method for identification of proteins from intracellular bacteria - Google Patents

Method for identification of proteins from intracellular bacteria Download PDF

Info

Publication number
WO2002082091A3
WO2002082091A3 PCT/DK2002/000234 DK0200234W WO02082091A3 WO 2002082091 A3 WO2002082091 A3 WO 2002082091A3 DK 0200234 W DK0200234 W DK 0200234W WO 02082091 A3 WO02082091 A3 WO 02082091A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
secreted
intracellular bacteria
identification
identified
Prior art date
Application number
PCT/DK2002/000234
Other languages
French (fr)
Other versions
WO2002082091A2 (en
Inventor
Allan Christian Shaw
Brian Berg Vandahl
Original Assignee
Allan Christian Shaw
Brian Berg Vandahl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allan Christian Shaw, Brian Berg Vandahl filed Critical Allan Christian Shaw
Priority to KR10-2003-7013236A priority Critical patent/KR20040002905A/en
Priority to MXPA03009222A priority patent/MXPA03009222A/en
Priority to IL15813602A priority patent/IL158136A0/en
Priority to EP02759766A priority patent/EP1412757A2/en
Priority to BR0208786-3A priority patent/BR0208786A/en
Priority to CA002443813A priority patent/CA2443813A1/en
Priority to JP2002579810A priority patent/JP2004534526A/en
Publication of WO2002082091A2 publication Critical patent/WO2002082091A2/en
Publication of WO2002082091A3 publication Critical patent/WO2002082091A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)

Abstract

The present invention relates to a novel combination of methods that enables identification of proteins secreted from intracellular bacteria regardless of the secretion pathway. The invention further provides proteins that are identified by these methods. Secreted proteins are known to be suitable candidates for inclusion in immunogenic compositions and/or diagnostic purposes. The invention also provides peptide epitopes (T-cell epitopes) from the identified secreted proteins, as well as nucleic acid compounds that encode the proteins. The invention further comprises various applications of the proteins or fragments thereof, such as pharmaceutical and diagnostic applications.
PCT/DK2002/000234 2001-04-09 2002-04-09 Method for identification of proteins from intracellular bacteria WO2002082091A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR10-2003-7013236A KR20040002905A (en) 2001-04-09 2002-04-09 Method for identification of proteins from intracellular bacteria
MXPA03009222A MXPA03009222A (en) 2001-04-09 2002-04-09 Method for identification of proteins from intracellular bacteria.
IL15813602A IL158136A0 (en) 2001-04-09 2002-04-09 Method for identification of proteins from intracellular bacteria
EP02759766A EP1412757A2 (en) 2001-04-09 2002-04-09 Method for identification of proteins from intracellular bacteria
BR0208786-3A BR0208786A (en) 2001-04-09 2002-04-09 Method for identification of intracellular bacterial proteins
CA002443813A CA2443813A1 (en) 2001-04-09 2002-04-09 Method for identification of proteins from intracellular bacteria
JP2002579810A JP2004534526A (en) 2001-04-09 2002-04-09 Methods for identifying proteins from intracellular bacteria

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28251301P 2001-04-09 2001-04-09
US60/282,513 2001-04-09
DKPA200100581 2001-04-09
DKPA200100581 2001-04-09

Publications (2)

Publication Number Publication Date
WO2002082091A2 WO2002082091A2 (en) 2002-10-17
WO2002082091A3 true WO2002082091A3 (en) 2004-03-04

Family

ID=26069005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000234 WO2002082091A2 (en) 2001-04-09 2002-04-09 Method for identification of proteins from intracellular bacteria

Country Status (9)

Country Link
EP (1) EP1412757A2 (en)
JP (1) JP2004534526A (en)
KR (1) KR20040002905A (en)
CN (1) CN1531653A (en)
BR (1) BR0208786A (en)
CA (1) CA2443813A1 (en)
IL (1) IL158136A0 (en)
MX (1) MXPA03009222A (en)
WO (1) WO2002082091A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP2517725A1 (en) 2007-05-01 2012-10-31 Board Of Regents, The University Of Texas Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease
US7892567B2 (en) 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease
WO2010042206A1 (en) 2008-10-09 2010-04-15 Board Of Regents, University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
CA2785300A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102749233A (en) * 2012-06-04 2012-10-24 王新华 Pretreatment method for directly detecting infection urine pathogen by MALDI-TOF MS
NL2019320B1 (en) * 2017-03-02 2018-09-21 Biosparq B V Diagnostic method and system for diagnosis
CN112175955B (en) * 2020-10-29 2022-05-24 西南大学 Strong promoter CP09 specifically expressed in plant pollen and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009006A1 (en) * 1997-08-15 1999-02-25 Soucy Francois SYNTHESIS OF CLASTO-LACTACYSTIN β-LACTONE AND ANALOGS THEREOF
WO1999027105A2 (en) * 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO1999028475A2 (en) * 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009006A1 (en) * 1997-08-15 1999-02-25 Soucy Francois SYNTHESIS OF CLASTO-LACTACYSTIN β-LACTONE AND ANALOGS THEREOF
WO1999027105A2 (en) * 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO1999028475A2 (en) * 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GEGINAT G ET AL: "A novel approach of direct ex vivo epitope mapping identifies dominant and subdominant CD4 and CD8 T cell epitopes from Listeria monocytogenes.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 FEB 2001, vol. 166, no. 3, 1 February 2001 (2001-02-01), pages 1877 - 1884, XP002227341, ISSN: 0022-1767 *
HESS J ET AL: "VACCINATION STRATEGIES AGAINST INTRACELLULAR MICROBES", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 7, no. 2, 1 August 1993 (1993-08-01), pages 95 - 103, XP002052092, ISSN: 0928-8244 *
SHAW ALLAN C ET AL: "Genetic differences in the Chlamydia trachomatis tryptophan synthase alpha-subunit can explain variations in serovar pathogenesis.", MICROBES AND INFECTION, vol. 2, no. 6, May 2000 (2000-05-01), pages 581 - 592, XP002193164, ISSN: 1286-4579 *
SHAW ALLAN CHRISTIAN ET AL: "Effects of interferon gamma on Chlamydia trachomatis serovar A and L2 protein expression investigated by two-dimensional gel electrophoresis.", ELECTROPHORESIS, vol. 20, no. 4-5, April 1999 (1999-04-01), pages 775 - 780, XP001065244, ISSN: 0173-0835 *
SIJTS ALICE J A M ET AL: "CTL epitope generation is tightly linked to cellular proteolysis of a Listeria monocytogenes antigen.", JOURNAL OF IMMUNOLOGY, vol. 156, no. 4, 1996, pages 1497 - 1503, XP001064234, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
JP2004534526A (en) 2004-11-18
EP1412757A2 (en) 2004-04-28
KR20040002905A (en) 2004-01-07
WO2002082091A2 (en) 2002-10-17
BR0208786A (en) 2004-03-09
CN1531653A (en) 2004-09-22
CA2443813A1 (en) 2002-10-17
MXPA03009222A (en) 2004-11-12
IL158136A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
WO2001031019A3 (en) Neisserial antigenic peptides
PL366826A1 (en) Reducing the immunogenicity of fusion proteins
EP2330129A3 (en) Anti-TNF antibodies, compositions, methods and uses
WO2002082091A3 (en) Method for identification of proteins from intracellular bacteria
WO2005071088A3 (en) Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
WO2004033659A3 (en) Novel tumor suppressor gene and compositions and methods for making and using the same
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
EP2287177A3 (en) Streptococcus agalactiae antigens I + II
WO2003030821A3 (en) Albumin fusion proteins
DK0726955T3 (en) Chimeric proteins, which include Borrelia polypeptides, and their applications
WO2003020894A3 (en) Insulin related transcription factor and uses thereof
AU2002353775A1 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
WO2002024739A3 (en) Spas-1 cancer antigen
WO2005030793A3 (en) Antibodies which bind human cxcr3
WO2001083739A3 (en) Human pellino polypeptides
WO2002016599A3 (en) Proteins and nucleic acids encoding same
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
WO2004085466A3 (en) Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
WO2002018576A3 (en) Compositions and methods relating to lung specific genes
WO2001066747A8 (en) Proteins named fctrx and nucleic acids encoding same
EP1265073A3 (en) Methods for determining plasma free drug concentration
WO2002022663A3 (en) Stress resistant retroviruses
WO2003042656A3 (en) Identifying and reducing the allergenicity of food proteins
WO2001074851A3 (en) Novel proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002338351

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 158136

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002579810

Country of ref document: JP

Ref document number: 2443813

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/009222

Country of ref document: MX

Ref document number: 1020037013236

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 028091140

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002759766

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002759766

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002759766

Country of ref document: EP